The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

被引：61

作者：

Meyer, Paul N. ^{[1
]}

Fu, Kai ^{[1
]}

Greiner, Timothy ^{[1
]}

Smith, Lynette ^{[2
]}

Delabie, Jan ^{[4
]}

Gascoyne, Randy ^{[5
]}

Ott, German ^{[6
,7
]}

Rosenwald, Andreas ^{[8
]}

Braziel, Rita ^{[9
]}

Campo, Elias ^{[10
]}

Vose, Julie ^{[3
]}

Lenz, Georg ^{[11
]}

Staudt, Louis ^{[12
]}

Chan, Wing ^{[1
]}

Weisenburger, Dennis D. ^{[1
]}

机构：

[1] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA

[2] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE 68198 USA

[3] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA

[4] Univ Oslo, Rikshosp, Radiumhosp Med Ctr, Dept Pathol, N-0027 Oslo, Norway

[5] British Columbia Canc Agcy, Dept Pathol, Vancouver, BC V5Z 4E6, Canada

[6] Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany

[7] Inst Clin Pharmacol, Stuttgart, Germany

[8] Univ Wurzburg, Dept Pathol, D-8700 Wurzburg, Germany

[9] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA

[10] Univ Barcelona, Dept Pathol, Hosp Clin, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain

[11] Univ Med Berlin, Mol Canc Res Ctr, Berlin, Germany

[12] NCI, Dept Pathol, Div Canc Treatment & Diag, Ctr Canc Res, Bethesda, MD 20892 USA

来源：

AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2011年 / 135卷 / 01期

关键词：

Diffuse large B-cell lymphoma; SPARC; Prognosis; CD68; Stromal cells; Microenvironment; Tumor markers; biological; MACROPHAGE-ASSOCIATED ANTIGEN; TUMOR-ASSOCIATED MACROPHAGES; FOLLICULAR LYMPHOMA; EXPRESSION; CLASSIFICATION; SIGNATURE; NEOPLASMS; BINDING;

D O I：

10.1309/AJCPJX4BJV9NLQHY

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The cellular composition of the tumor microenvironment may affect survival in diffuse large B-cell lymphoma (DLBCL). We performed immunostains for 2 stromal cell markers, CD68 and SPARC (secreted protein, acidic and rich in cysteine), in 262 patients with DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapies. Patients with any SPARC+ cells in the microenvironment had a significantly longer overall survival, and patients with high SPARC positivity in the microenvironment also had a significantly longer event free survival. Survival differences were mainly due to the prognostic effect of SPARC+ cells in activated B-cell (ABC)-type DLBCL, with no effect found in the germinal center B-cell type DLBCL. Of clinical features examined, only the number of extranodal sites was significantly associated with SPARC expression. Multivariate analysis revealed that SPARC expression predicted patient survival independent of the International Prognostic Index or tumor cell of origin. SPARC expression in the microenvironment of DLBCL can be used for prognostic purposes, determining a subgroup of patients with ABC DLBCL who have significantly longer survival. More aggressive chemotherapy protocols should be considered for patients with ABC DLBCL without SPARC+ stromal cells. CD68 expression by cells in the microenvironment did not predict survival.

引用

页码：54 / 61

页数：8

共 36 条

[1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[2] SPARC: a matricellular regulator of tumorigenesis [J].

Arnold, Shanna A. ;

Brekken, Rolf A. .

JOURNAL OF CELL COMMUNICATION AND SIGNALING, 2009, 3 (3-4) :255-273

[3] SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength [J].

Bradshaw, AD ;

Puolakkainen, P ;

Dasgupta, J ;

Davidson, JM ;

Wight, TN ;

Sage, EH .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 120 (06) :949-955

[4] The microenvironment in mature B-cell malignancies: a target for new treatment strategies [J].

Burger, Jan A. ;

Ghia, Paolo ;

Rosenwald, Andreas ;

Caligaris-Cappio, Federico .

BLOOD, 2009, 114 (16) :3367-3375

[5] Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling [J].

Byers, Richard J. ;

Sakhinia, Ebrahim ;

Joseph, Preethi ;

Glennie, Caroline ;

Hoyland, Judith A. ;

Menasce, Lia P. ;

Radford, John A. ;

Illidge, Timothy .

BLOOD, 2008, 111 (09) :4764-4770

[6]

CHLENSKI A, 2009, SEMIN CELL DEV BIOL

[7] A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy [J].

Choi, William W. L. ;

Weisenburger, Dennis D. ;

Greiner, Timothy C. ;

Piris, Miguel A. ;

Banham, Alison H. ;

Delabie, Jan ;

Braziel, Rita M. ;

Geng, Huimin ;

Iqbal, Javeed ;

Lenz, Georg ;

Vose, Julie M. ;

Hans, Christine P. ;

Fu, Kai ;

Smith, Lynette M. ;

Li, Min ;

Liu, Zhongfeng ;

Gascoyne, Randy D. ;

Rosenwald, Andreas ;

Ott, German ;

Rimsza, Lisa M. ;

Campo, Elias ;

Jaffe, Elaine S. ;

Jaye, David L. ;

Staudt, Louis M. ;

Chan, Wing C. .

CLINICAL CANCER RESEARCH, 2009, 15 (17) :5494-5502

[8] Rituximab therapy in malignant lymphoma [J].

Coiffier, B. .

ONCOGENE, 2007, 26 (25) :3603-3613

[9] General morphological and biological features of neoplasms: integration of molecular findings [J].

Diaz-Cano, S. J. .

HISTOPATHOLOGY, 2008, 53 (01) :1-19

[10] Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein [J].

DiMartino, JF ;

Lacayo, NJ ;

Varadi, M ;

Li, L ;

Saraiya, C ;

Ravindranath, Y ;

Yu, R ;

Sikic, B ;

Raimondi, SC ;

Dahl, G .

LEUKEMIA, 2006, 20 (03) :426-432

← 1 2 3 4 →